Thursday, 03 September 2026 12:15 PM
Regulatory
Medford business says proposed fees could cost it a manufacturing license and drive as many as half of its facilitators from the regulated industry
ASHLAND, OR / ACCESS Newswire / September 3, 2026 / Satya Therapeutics is challenging the financial basis for Oregon Health Authority rules that would double major psilocybin licensing fees, adding $22,000 a year to Satya's licensing costs and likely forcing the company to surrender its manufacturing license in July, 2027.
The OHA proposed rules would increase annual service-center and manufacturer license fees from $10,000 to $20,000 and facilitator fees from $2,000 to $4,000. Facilitators who have been paying "reduced fees" will see their cost go from $1,000 to $4,000.
Satya estimates that as many as half of the facilitators currently working with its service center may be forced to leave the regulated industry if the annual facilitator fee doubles.
"This isn't an abstract policy discussion for us," said Satya co-founder and licensed facilitator Andreas Met. "A $20,000 manufacturing license may force us to give up that license, and as many as half of the facilitators working with Satya will no longer be able to justify remaining licensed at $4,000 a year."
Satya Asks OHA: Show Us the Math
OHA says higher licensing fees are necessary because the Oregon Psilocybin Services program is not financially self-sustaining.
But OHA also acknowledges in its proposed-rule notice that higher fees may reduce the number of licensees and could create a more significant program budget shortfall.
"OHA is proposing to solve a budget problem by dramatically increasing what the remaining businesses and facilitators have to pay, while acknowledging that doing so may drive licensees out and make the budget problem worse," Met said. "If doubling the fees makes the program financially sustainable, show us the math."
The issue of attrition was repeatedly raised during OHA's Rules Advisory Committee process in July. Participants questioned OHA about licensee nonrenewal, program revenue and economic impacts, and proposed alternatives including tiered fees, revenue-based fees and installment payments.
OHA's September 1 Notice nevertheless states that the overall fiscal and economic impact of the proposed rules "cannot be quantified at this time," while acknowledging that the impact is likely to be significant.
"OHA cannot simply multiply a higher fee by today's number of licensees," Met said. "It needs to determine how many of those licensees will actually renew. At Satya alone, we're looking at potentially surrendering our manufacturing license while as many as half of our facilitators will leave the industry. That will diminish our ability to serve clients, and will certainly make it more difficult for Satya to make the program accessible to people from all walks or life--something we have prided ourselves with over the past three and a half years."
Financial Records Still Sought
On July 18, Met submitted a public-records request seeking OPS budgets, revenues, expenditures, staffing information, financial models supporting the proposed fee schedule and related financial records. Those records have not yet been produced.
On September 1, Met formally asked OHA to disclose and clarify the financial basis for the proposed fees and invoked ORS 183.335(4), requesting a 30-day postponement of the agency's intended action to allow additional time for affected parties to submit data, views and arguments.
Satya is asking OHA to disclose the financial analysis supporting the proposed fees, explain the renewal and attrition assumptions used to develop them, and provide licensees a meaningful opportunity to evaluate that information before adoption.
"We want Oregon's regulated psilocybin program to succeed," Met said. "But the state cannot make the program sustainable by making the people and businesses supporting it unsustainable. If OHA has analysis showing these fees will work, release it. If that analysis doesn't exist, Oregon should know that before the fees are adopted. These fee increases have been widely opposed by industry operators who--like Satya--have poured their hearts, effort, and resources into a program that does so much to help people. This is a struggle for the industry's survival and we must make every effort to sustain the industry."
About Satya Therapeutics
Satya Therapeutics is an Oregon-licensed psilocybin service center and manufacturer based in Ashland, Oregon.
Contact: Andreas Met (541) 930-2478, [email protected], www.satyatherapeutics.com
SOURCE: SATYA INC.